Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person16
CITIUS ONCOLOGY, INC.
Company
CG Oncology, Inc.
Company
Coherus Oncology, Inc.
Company
Kura Oncology, Inc.
Company
Cardiff Oncology, Inc.
Company
Pyxis Oncology, Inc.
Company
Aktis Oncology, Inc.
Company
CHAMPIONS ONCOLOGY, INC.
Company
Starling Oncology, Inc.
Company
ALX ONCOLOGY HOLDINGS INC
Company
CITIZENS, INC.
Company
CITIGROUP INC
Company
Onconetix, Inc.
Company
Citius Pharmaceuticals, Inc.
Company
Cibus, Inc.
Company
BridgeBio Oncology Therapeutics, Inc.
Company
Primary record11
CITIUS ONCOLOGY, INC. filed 8-K
Item 8.01 Other Events. On November 4, 2026, Citius Oncology, Inc. issued a press release announcing health-related quality of life results from pivotal Study 302 of LYMPHIR® (denileukin diftitox-cxdl) in adults with rel
Citius Pharmaceuticals, Inc. filed 8-K
Item 8.01 Other Events. On November 4, 2026, our majority-owned subsidiary, Citius Oncology, Inc., issued a press release announcing health-related quality of life results from pivotal Study 302 of LYMPHIR® (denileukin d
CITIUS ONCOLOGY, INC. filed 8-K
Item 2.02. Results of Operations and Financial Condition. On October 26, 2026, Citius Oncology, Inc. issued a press release announcing preliminary, unaudited LYMPHIR ® (denileukin diftitox-cxdl) unit sales to U.S. wholes
Citius Pharmaceuticals, Inc. filed 8-K
Item 2.02. Results of Operations and Financial Condition. On October 26, 2026, our wholly-owned subsidiary, Citius Oncology, Inc., issued a press release announcing preliminary, unaudited LYMPHIR ® (denileukin diftitox-c
CITIUS ONCOLOGY, INC. filed 8-K
Item 8.01 Other Events. On October 19, 2026, Citius Oncology, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted its request for an extension through April 19, 2027 (the “Exte
CITIUS ONCOLOGY, INC. filed 8-K
Item 5.07. Submission of Matters to a Vote of Security Holders. On September 29, 2026, Citius Oncology, Inc. (the Company ) held its 2026 annual meeting of stockholders (the Annual Meeting ). At the Annual Meeting, our s
CITIUS ONCOLOGY, INC. filed DEF 14A
SEC form DEF 14A filed by CITIUS ONCOLOGY, INC. (CIK 1851484) on 2026-08-26.
ARMISTICE CAPITAL, LLC filed SCHEDULE 13G/A
0001172661-26-003568.txt : 20260814 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001172661-26-002138 0001601086 XXXXXXXX LIVE 4 Common Stock 06/30/2026 0001851484 Citius Oncology, Inc. 17331Y109 11 COMMERCE DRI
CITIUS ONCOLOGY, INC. filed 8-K
Item 2.02. Results of Operations and Financial Condition. On August 14, 2026, Citius Oncology, Inc. issued a press release announcing our results of operations for the third quarter of fiscal 2026. A copy of the press re
CITIUS ONCOLOGY, INC. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On August 7, 2026, the Board of Directors (the Board ) of C
CITIUS ONCOLOGY, INC. filed 8-K
Item 8.01 Other Events. On August 5, 2026, Citius Oncology, Inc. issued a press release announcing an update on the expanding base of institutional accounts ordering LYMPHIR . A copy of the press release is furnished as